Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based 'Newco,' explain experts at Orrick.

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Chris Anzalone It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

By Barry Teater Free advice and mentoring from seasoned life science executives are helping some firsttime bioscience entrepreneurs in North Carolina find success for their young companies. The North ...

Changing healthcare provider (HCP) and patient expectations have disrupted conventional customer engagement methods across the entire healthcare ecosystem. The traditional reach and frequency model ...

This article is part one of a two-part series. Part two is available here. Part 1: AI for rapid Drug Discovery In the rapidly evolving landscape of pharmaceutical development, AI promises to ...